GALAPAGOS NV/S (NASDAQ:GLPG) had its price objective lifted by Royal Bank of Canada to $171.00 in a research report released on Monday, The Fly reports.
Several other research analysts have also issued reports on GLPG. Cowen reissued a buy rating on shares of GALAPAGOS NV/S in a research report on Friday, July 26th. Stifel Nicolaus increased their price target on shares of GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a buy rating in a research report on Monday, July 15th. HC Wainwright increased their price target on shares of GALAPAGOS NV/S from $150.00 to $205.00 and gave the stock a buy rating in a research report on Monday, July 15th. Cantor Fitzgerald reissued a buy rating and issued a $130.00 price target on shares of GALAPAGOS NV/S in a research report on Thursday, May 2nd. Finally, Credit Suisse Group reissued an outperform rating on shares of GALAPAGOS NV/S in a research report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $156.45.
Shares of GLPG traded down $1.25 during trading hours on Monday, reaching $172.98. 2,015 shares of the company traded hands, compared to its average volume of 326,657. The firm has a fifty day moving average of $148.13. The firm has a market cap of $8.93 billion, a PE ratio of -262.26 and a beta of 1.54. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02. GALAPAGOS NV/S has a 1-year low of $85.00 and a 1-year high of $191.63.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Article: Consumer behavior in bull markets
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.